second-line treatment

Open Access
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases
GAKU YAMAMICHI, TAIGO KATO, AKIHIRO YOSHIMURA, MASARU TANI, YUKI HORIBE, YUTONG LIU, NESRINE SASSI, YOHEI OKUDA, TOSHIKI OKA, TOSHIHIRO UEMURA, AKINARU YAMAMOTO, YU ISHIZUYA, TAKUJI HAYASHI, YOSHIYUKI YAMAMOTO, KOJI HATANO, ATSUNARI KAWASHIMA, TETSUYA TAKAO, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA and NORIO NONOMURA

Anticancer Research February 2025, 45 (2) 639-650; DOI: https://doi.org/10.21873/anticanres.17451
You have access
Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study
SUNG HEE LIM, JUNG YONG HONG, JOON OH PARK, YOUNG SUK PARK and SEUNG TAE KIM

Anticancer Research September 2023, 43 (9) 4161-4167; DOI: https://doi.org/10.21873/anticanres.16607
You have access
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII

Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
You have access
Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis
TAIKO NAKAZAWA, YUKIYA NARITA, RYOSUKE KUMANISHI, TAKATSUGU OGATA, YUKI MATSUBARA, KAZUKI NOZAWA, KYOKO KATO, KAZUNORI HONDA, TOSHIKI MASUISHI, HIDEAKI BANDO, SHIGENORI KADOWAKI, MASASHI ANDO, KAZUO HARA, MASAHIRO TAJIKA and KEI MURO

Anticancer Research October 2021, 41 (10) 5147-5155; DOI: https://doi.org/10.21873/anticanres.15332
You have access
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients
UROS MARKOVIC, ANNA BULLA, SALVATORE LEOTTA, STEFANIA STELLA, MARIA LETIZIA CONSOLI, LOREDANA TAMBÈ, CONCETTA CONTICELLO, FRANCESCO DI RAIMONDO and FABIO STAGNO

Anticancer Research September 2020, 40 (9) 5313-5317; DOI: https://doi.org/10.21873/anticanres.14538
You have access
Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial
CESARE GRIDELLI, ANTONIO CHELLA, GIUSEPPE VALMADRE, GIACOMO ALLEGRINI, MATTEO BRIGHENTI, PAOLO BIDOLI, ANTONIO ROSSI, PAOLO MAIONE, MARIA RITA MIGLIORINO, SERENA RICCIARDI and FILIPPO DE MARINIS

Anticancer Research December 2016, 36 (12) 6535-6540;
You have access
Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene
ONDREJ FIALA, MILOS PESEK, JINDRICH FINEK, MARTIN SVATON, MAREK MINARIK, LUCIE BENESOVA, ZBYNEK BORTLICEK, RADEK KUCERA and ONDREJ TOPOLCAN

Anticancer Research January 2016, 36 (1) 447-453;

Main menu

User menu

Search

second-line treatment